Table 1.
Cumulative incidence of myocarditis/pericarditis within 1–21 days after SARS-CoV-2 vaccination, by vaccine product and dose.
| Vaccine | Vaccination schedule | Events | Number of persons vaccinateda | Cumulative incidence per 100,000 persons (95% CI) | Number of doses administered |
Cumulative incidence per million doses (95% CI) |
|---|---|---|---|---|---|---|
| BNT162b2 | Primary series | |||||
| Dose 1 | 26 | 13,573,466 | 0.19 (0.13, 0.28) | 13,573,466 | 1.92 (1.25, 2.81) | |
| Dose 2 | 31 | 13,388,261 | 0.23 (0.16, 0.33) | 13,388,261 | 2.32 (1.57, 3.29) | |
| Booster dose | ||||||
| Dose 3 | 10 | 11,861,042 | 0.08 (0.04, 0.16) | 11,861,042 | 0.84 (0.40, 1.55) | |
| Homologous b | 4 | 5,257,500 | 0.07 (0.02, 0.19) | 5,257,500 | 0.76 (0.21, 1.95) | |
| Heterologous c | 6 | 6,603,542 | 0.09 (0.03, 0.19) | 6,603,542 | 0.91 (0.33, 1.98) | |
| Total | 67 | 20,177,088 | 0.33 (0.26, 0.42) | 38,822,769 | 1.73 (1.34, 2.19) | |
| CoronaVac | Primary series | |||||
| Dose 1 | 10 | 9,881,811 | 0.10 (0.05, 0.19) | 9,881,811 | 1.01 (0.49, 1.86) | |
| Dose 2 | 4 | 9,798,795 | 0.04 (0.01, 0.11) | 9,798,795 | 0.41 (0.11 (1.05) | |
| Booster dose | ||||||
| Dose 3 | 1 | 1,107,802 | 0.09 (0.00, 0.50) | 1,107,802 | 0.90 (0.02, 5.03) | |
| Homologous b | 1 | 1,089,606 | 0.09 (0.00, 0.51) | 1,089,606 | 0.92 (0.02, 5.11) | |
| Heterologous c | – | 18,196 | NA | 18,196 | NA | |
| Total | 15 | 9,900,007 | 0.15 (0.09, 0.25) | 20,788,408 | 0.72 (0.40, 1.19) | |
| ChAdOx1 | Primary series | |||||
| Dose 1 | 1 | 2,040,770 | 0.05 (0.00, 0.27) | 2,040,770 | 0.49 (0.01, 2.73) | |
| Dose 2 | 2 | 2,023,822 | 0.09 (0.01, 0.36) | 2,023,822 | 0.99 (0.12, 3.57) | |
| Booster dose | ||||||
| Dose 3 | 2 | 1,517,906 | 0.13 (0.02, 0.48) | 1,517,906 | 1.32 (0.16, 4.76) | |
| Homologous b | 1 | 728,337 | 0.14 (0.00, 0.77) | 728,337 | 1.37 (0.03, 7.65) | |
| Heterologous c | 1 | 789,569 | 0.13 (0.00, 0.71) | 789,569 | 1.27 (0.03, 7.06) | |
| Total | 5 | 2,830,339 | 0.18 (0.06, 0.41) | 5,582,498 | 0.90 (0.29, 2.09) |
a
Defined as total persons who received the vaccine as 1st dose, 2nd dose, or 3rd doses. Person who received 3 vaccine doses contributed to dose 1, dose 2, and dose 3 categories. Total number of persons vaccinated was the sum of individuals who received at least one dose of the vaccine for the primary series and/or booster dose.
b
Refers to vaccine administered as the booster dose is the same type as the first and second doses (e.g., BNT162b2/BNT162b2/BNT162b2).
c
Refers to vaccine administered as the booster dose is different as the first and second doses (e.g., CoronaVac/CoronaVac/BNT162b2).